US OptionsDetailed Quotes
ELDN241220P5000
- 0.71
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
0.71Open0.71Pre Close0 Volume10 Open Interest5.00Strike Price0.00Turnover0.00%IV-0.70%PremiumDec 20, 2024Expiry Date0.74Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Eledon Pharmaceuticals Stock Discussion
Sign in to post a comment
$Eledon Pharmaceuticals (ELDN.US)$ dont sleep on nice under the rader climber
1
$Eledon Pharmaceuticals (ELDN.US)$ moon time🚀🚀🚀🚀🚀
$Eledon Pharmaceuticals (ELDN.US)$ Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
4 MINUTES AGO, 7:46 AM EDT
VIA GLOBENEWSWIRE
4 MINUTES AGO, 7:46 AM EDT
VIA GLOBENEWSWIRE
1
4
$Eledon Pharmaceuticals (ELDN.US)$ Reuters· 2 mins ago
Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine
Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine
1
$Eledon Pharmaceuticals (ELDN.US)$ Reuters· 5 mins ago
Eledon Announces Completion of Enrollment in Phase 2 Bestow Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 Bestow Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
1
$Eledon Pharmaceuticals (ELDN.US)$
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
$Eledon Pharmaceuticals (ELDN.US)$
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
$Eledon Pharmaceuticals (ELDN.US)$ Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Benzinga· 2 mins ago
Benzinga· 2 mins ago
1
No comment yet
Z00M00 : what does dont sleep on nice under the rader climber mean?